1-t-butyl-4-(trimethylstannyl)-1,2,3,6-tetrahydropyridine | 444664-66-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-t-butyl-4-(trimethylstannyl)-1,2,3,6-tetrahydropyridine
• 英文别名: 1-tert-butyl-4-(trimethylstannyl)-1,2,3,6-tetrahydropyridine；1-tert-Butyl-1,2,3,6-tetrahydro-4-(trimethylstannyl)pyridine；(1-tert-butyl-3,6-dihydro-2H-pyridin-4-yl)-trimethylstannane
• CAS: 444664-66-8
• 化学式: C₁₂H₂₅NSn
• 分子量: 302.047
• InChiKey: OBYQKDCBJLUUDH-UHFFFAOYSA-N

物化性质

• 沸点：
  280.3±50.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.29
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  8-bromo-6-chloro-1-(2,6-dichlorophenyl)-2H-quinolizin-2-one 、 1-t-butyl-4-(trimethylstannyl)-1,2,3,6-tetrahydropyridine 在 bis-triphenylphosphine-palladium(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 8-(1-tert-butyl-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1-(2,6-dichlorophenyl)-2H-quinolizin-2-one
  参考文献：
  名称：

  WO2007/21710

  摘要：

  公开号：

文献信息

• (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
  申请人：——

  公开号：US20030092712A1

  公开（公告）日：2003-05-15

  Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: 1 are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.

  根据化学公式(I)或其药物可接受的盐描述的化合物： 1 是p38的抑制剂，可用于治疗类风湿性关节炎等炎症性疾病。
• 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists
  申请人：Bao Jianming

  公开号：US20090286777A1

  公开（公告）日：2009-11-19

  The present invention is directed to certain 5,6-fused pyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些5,6-融合吡咯烷化合物，其作为神经激肽-1（NK-1）受体拮抗剂和缓激肽，特别是物质P的抑制剂具有用途。本发明还涉及含有这些化合物作为活性成分的制药配方以及这些化合物和它们的配方在治疗某些疾病，包括恶心、尿失禁、抑郁症和焦虑症中的应用。
• P38 KINASE INHIBITING AGENTS
  申请人：Chen Meng-Hsin

  公开号：US20110183959A1

  公开（公告）日：2011-07-28

  Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

  化学式（I）所描述的化合物或其药学上可接受的盐：是p38抑制剂，并可用于治疗炎症，例如治疗类风湿性关节炎、类风湿性脊柱炎、骨关节炎、痛风性关节炎和其他关节炎症状；炎症性关节、湿疹、牛皮癣或其他炎症性皮肤病，如晒伤；炎症性眼部疾病，包括结膜炎；发热、疼痛和其他与炎症相关的疾病。
• P38 kinase inhibiting agents
  申请人：Merk Sharp & Dohme Corp.

  公开号：US07879875B2

  公开（公告）日：2011-02-01

  Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

  化学式(I)描述的化合物或其药学上可接受的盐：(I)是p38的抑制剂，可用于治疗炎症，例如治疗类风湿性关节炎，类风湿性脊柱炎，骨关节炎，痛风性关节炎和其他关节炎症状; 发炎的关节，湿疹，牛皮癣或其他炎症性皮肤病，如晒伤; 炎症性眼部疾病，包括结膜炎; 发热，疼痛和其他与炎症相关的病症。
• Furo[3,2-C]pyridines
  申请人：OSI Pharmaceuticals, LLC

  公开号：US08022206B2

  公开（公告）日：2011-09-20

  Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET.

  本发明涉及式I的Furo[3,2-c]吡啶和Thieno[3,2-c]吡啶化合物，以及其药学上可接受的盐、制备方法、中间体、制药组合物和用途，例如在疾病治疗中，包括癌症，包括涉及EMT的病症，包括由蛋白激酶活性介导的病症，例如RON和/或MET。